News

The GEUS-COMPASS project's main objective is to accelerate the development of a multimodal test to transform cancer detection before symptoms appear. It aims to identify early molecular signs of colorectal, lung, and breast cancer in a single process.

GEUS-COMPASS is a project that integrates genomics, epigenomics, epidemiology, and other advanced omics layers with cutting-edge artificial intelligence to develop next-generation predictive tools. This multidimensional approach represents a major step forward in expanding GEUS technology toward integrated and accessible diagnostics.

This project is jointly led by Víctor Moreno's group, the IGTP (Institute of Genomics and Tropical Medicine), and the company Aniling, and is funded by the Spanish State Research Agency and European funds.

https://www.aniling.com/m/geus-compass-shaping-the-future-of-early-cancer-detection/

A new tool has been validated that could facilitate the early detection of pancreatic cancer, one of the most aggressive and difficult-to-diagnose tumors. The research team, with a prominent role played by the PADO (Pancreatic Cancer Assessment Program), developed the tool, the statistical analysis, and the integration of epidemiological data. The study, published in the Journal of Epidemiology, has verified a scoring system based on 24 epidemiological factors that allows for the identification of individuals at higher risk of developing pancreatic cancer.

The work focused on individuals with a high familial risk of developing this disease and was validated using data from nearly 300,000 participants in the UK Biobank. The results show that individuals with higher scores were more likely to have suspicious lesions detected by magnetic resonance imaging (MRI). Therefore, strategies like this can be particularly useful for focusing efforts on high-risk groups.

https://pubmed.ncbi.nlm.nih.gov/42160519/

https://www.linkedin.com/feed/update/urn:li:activity:7475836624363397120

The Hereditary Cancer group at ICO-IDIBELL continues its work on improving the diagnostic strategy for unresolved cases of hereditary cancer, in this instance by applying its own algorithm to identify complex mutations that are difficult to detect. The approach of this study is based on the optimisation of current bioinformatics tools (GRIDSS) and has been published in the European Journal of Human Genetics. The study, led by Dr Conxi Lázaro, involved the participation of UBOP (David Cordero, Ania Alay, José Marcos Moreno and María Ajenjo).

On April 29 and 30, the European consortium TANGERINE, led by Dr. Víctor Moreno, held its final follow-up meeting at the Henri Mondor Hospital in Créteil, France.

This initiative, launched in 2023, brings together teams from five countries (Spain, France, Germany, Romania, and Israel) with the goal of developing an artificial intelligence tool capable of predicting the response and toxicity to immunotherapy in patients with different types of cancer.

This study was funded by the Carlos III Health Institute (ISCIII) under the "International Collaboration Projects" program, which finances actions of the Recovery and Resilience Facility (RRF), through project AC22/00021, by the Spanish Scientific Foundation, and by the European Union – NextGenerationEU.

Link to project

A new study led by researchers from ODAP Biomarkers and Susceptibility Unit, and published in Environmental International, has shed light on the specific interaction between genetics and the environment in the risk of developing colorectal cancer.

The development of colorectal cancer does not depend on a single factor but is the result of a complex interaction between genetics, the environment and individual lifestyle. The research, led by Ferran Moratalla as lead author, has focused on the effect of prolonged exposure to trihalomethanes —a common by-product of the water purification process—on the risk of developing colorectal cancer. According to the results, genetic variants have been identified that could modulate the body’s response to trihalomethanes and influence the risk of developing this cancer. Specifically, a variant related to the LRRC8B gene could play a significant role in the biological response to trihalomethanes, increasing susceptibility to colorectal cancer and modulating the risk of developing tumours.

Further research is needed to confirm these findings and to explore the biological mechanisms underlying the link between trihalomethanes exposure, genetics and the risk of developing colorectal cancer.